Why the OIG Just Revolutionized Pharma Marketing (And What It Costs You)
About this episode
This episode discusses the OIG's new regulations on pharmaceutical marketing and their implications for cash-paying patients.
Send us Fan Mail On January 27, 2026, the HHS Office of Inspector General (OIG) changed the game for pharmaceutical manufacturers. In a landmark Special Advisory Bulletin, the government officially opened a "green lane" for direct-to-patient (DTP) drug sales, specifically addressing the rise of cash-pay programs like TrumpRx. In this episode, we break down why the OIG is now prioritizing lower costs over traditional Anti-Kickback Statute (AKS) risks for cash-paying patients—including th...
More episodes of DarshanTalks Podcast
- Why Private Membership Associations Fail FDA Scrutiny
- The Hidden Reason Sites are Firing Recruiters
- Don’t Let Your PI Walk Away With Your Study
- Safe or Just "Not Dirty"? The Regulatory Gamble of Compounded Drugs
- "Basically Employees" Isn't a Legal Category (And the OIG Knows It)
- The Hidden Legal Risks of AI Sponsor Protocols
Explore listener stats, chart rankings, contacts and more on the DarshanTalks Podcast podcast page.